Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a pill help stop breast cancer from spreading after a local return?

NCT ID NCT07190443

Recruiting now Disease control Sponsor: Japanese Foundation for Cancer Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapy can prevent breast cancer from coming back or spreading in people whose cancer has returned in the same breast, chest wall, or nearby lymph nodes. About 290 participants will receive either hormone therapy alone or hormone therapy plus abemaciclib for two years. The study also looks at a blood test to detect leftover cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abemaciclib (a CDK4/6 inhibitor) taken as a pill
What this could lead to
If successful, this could establish a new standard treatment to reduce the risk of breast cancer returning or spreading after a local recurrence.
What could go wrong
This is a phase 3 trial, but results are not yet known. Adding abemaciclib may cause side effects like diarrhea or low blood cell counts, and it may not improve outcomes compared to endocrine therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABEMACICLIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABEMACICLIB BREAST CANCER ENDOCRINE THERAPY LOCOREGIONAL RECURRENCE

Contacts and locations

Locations

  • Cancer Institute Hospital of JFCR

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.